KYMR
Kymera Therapeutics, Inc. · Healthcare · Market cap $9.4B
Insiders sold $10.1M net in the last 90 days ·2 sellers, 0 buyers· 2 of 3 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 1, 2026
Insider Buying
$172.5M
reported purchases (SEC code P)
Insider Selling
$475.1M
reported sales (SEC code S)
Unique Insiders
12
in the rolling window
Latest filing
Oct 1, 2026
Mainolfi Nello
Kymera Therapeutics, Inc. (KYMR) has 53 SEC Form 4 filings (329 transaction rows) in the rolling window, disclosed by 12 distinct insiders. Most recent filing: Oct 1, 2026.
Inside the rolling window, 12 insiders at Kymera Therapeutics, Inc. reported 1 open-market purchase totaling $172.5M and 57 open-market sales totaling $475.1M. The most active filer is Director Booth Bruce with 15 filings. Insiders have net sold $405.7M over the trailing 6 months. The most recent open-market filing is a sale of 30,000 shares by Chief Executive Officer Mainolfi Nello, dated Oct 1, 2026, worth $3.4M.
- Industry:Biotechnology
- CEO:Nello Mainolfi
- Employees:273
- HQ:Watertown, MA, US
- IPO:2020-08-21
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer | Sale | 30,000 | $3.4M | Oct 1 | +3.0% | SEC ↗ | |
Adams BrianFirst filing | Chief Legal Officer | Sale | 6,371 | $744K | Sep 4 | -3.3% | SEC ↗ |
| Chief Executive Officer | Sale | 50,000 | $6.0M | Jul 8 | -0.6% | SEC ↗ | |
Jacobs Bruce N.First in 4 months | Chief Financial Officer | Sale | 77,109 | $8.9M | Jul 2 | — | SEC ↗ |
| Chief Business Officer | Sale | 3,389 | $387K | Jul 2 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 80,000 | $9.2M | Jul 2 | — | SEC ↗ | |
| Director | Sale | 153,300 | $16.6M | Jul 2 | — | SEC ↗ | |
| Director | Sale | 467,878 | $51.6M | Jun 30 | — | SEC ↗ | |
| See Remarks and Footnotes | Sale | 1,630,658 | $173.7M | Jun 26 | — | SEC ↗ | |
| Director | Sale | 548,321 | $65.1M | Jun 26 | — | SEC ↗ | |
| Director | Sale | 1,408 | $141K | Jun 26 | — | SEC ↗ | |
| Director | Sale | 134,720 | $13.5M | Jun 26 | — | SEC ↗ | |
| Chief Business Officer | Sale | 5,000 | $570K | Jun 25 | — | SEC ↗ | |
| Director | Sale | 278,128 | $27.6M | Jun 23 | — | SEC ↗ | |
| Director | Sale | 116,812 | $10.6M | Jun 23 | — | SEC ↗ | |
| Director | Sale | 115,056 | $10.5M | Jun 23 | — | SEC ↗ | |
| Chief Business Officer | Sale | 2,500 | $248K | Jun 22 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 12,905 | $1.0M | May 27 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 4,279 | $349K | May 27 | — | SEC ↗ | |
| Director | Sale | 3,000 | $261K | May 11 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 30,000 | $2.4M | Apr 29 | — | SEC ↗ | |
| Director | Sale | 6,000 | $540K | Apr 24 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 300 | $27K | Apr 24 | — | SEC ↗ | |
| Director | Sale | 4,159 | $374K | Apr 16 | — | SEC ↗ | |
| Director | Sale | 5,335 | $480K | Apr 16 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does KYMR have?
Kymera Therapeutics, Inc. (KYMR) has 53 SEC Form 4 filings (329 transaction rows) in the rolling 365-day window, disclosed by 12 distinct insiders. Most recent filing: Oct 1, 2026.
When was the most recent SEC Form 4 filing for KYMR?
The most recent Form 4 filing for KYMR on Tracefour is dated Oct 1, 2026.
Who is the most active insider at KYMR?
The most active SEC Form 4 filer at KYMR in the rolling window is Director Booth Bruce, with 15 filings.
What is the net insider flow at KYMR over the last 6 months?
Over the trailing 180 days, insiders at KYMR have net sold $405.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at KYMR in the current window?
Inside the rolling window, insiders at KYMR bought $172.5M and sold $475.1M based on SEC Form 4 filings.
Can I get alerts for KYMR insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Kymera Therapeutics, Inc. (KYMR). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Kymera Therapeutics, Inc. is in the Healthcare sector.